tapimmune is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. the company’s next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has t

Marker Therapeutics, Inc. Common Stock

Bought to close 68% MRKR

This member connected a brokerage account and is sharing trades and portfolio performance with the community. 

Public Portfolio

Gregg

Bought to close all MRKR

Sold short MRKR

Sold all MRKR

Abilash Satya

New position in MRKR

Zachary Rapp

Bull Investor

Jacob Kucera